CAPR

Capricor Therapeutics, Inc.

3.60 USD

Last updated Dec 10, 21:25 UTC

Yesterday HIGH

$3.7

Yesterday LOW

$3.38

52w HIGH

$8.22

52w LOW

$2.68

EPS

-0.25

PE

-14.40

Next Earnings

Mar 13, 2024

Overview News Government Trades

Capricor Therapeutics, Inc. stock is up 28.57% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 23.81% of the previous 21 December’s closed higher than November.

Capricor Therapeutics, Inc. focuses on the development of transformative cell and exosome-based therapeutics. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) The company also develops CAP-2003 that is in pre-clinical development for the. treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

San Mateo, United States Of America

Website

capricor.com

Lisa Levin

Wed Aug 23, 2023

Top 5 Health Care Stocks That May Fall Off A Cliff

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
richadhand@benzinga.com

Tue Aug 15, 2023

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $18 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $18 price target.
sunil@benzinga.com

Mon Aug 7, 2023

Capricor Therapeutics Q2 EPS $(0.29) Beats $(0.35) Estimate, Sales $3.92M Beat $1.50M Estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 17.14 percent. This is unchanged from the same period last year. The company
Benzinga Insights

Mon Aug 7, 2023

Earnings Scheduled For August 7, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss at $0.44 per share on revenue of $153.69 million.
Benzinga Newsdesk

Fri Jun 30, 2023

Capricor Therapeutics Announces 24-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy

-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of Cardiac Function- -Results in Performance of the Upper Limb PUL v2.0 Continue to Show Long-Term Benefit
Benzinga Newsdesk

Tue Jun 13, 2023

Capricor Therapeutics To Present 24-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today
Benzinga Newsdesk

Wed Jun 7, 2023

Capricor Therapeutics Announces Follow-Up Type-B Clinical Meeting With The FDA For CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases,
Benzinga Insights

Thu May 11, 2023

Recap: Capricor Therapeutics Q1 Earnings
totan@benzinga.com

Thu May 11, 2023

Capricor Therapeutics Q1 EPS $(0.31) Beats $(0.32) Estimate, Sales $2.99M Beat $500.00K Estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 3.13 percent increase over losses of $(0.32) per share
Benzinga Insights

Thu May 11, 2023

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.